Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on ...
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
However, positive early-stage results for its once weekly Amycretin obesity drug, which similarly employs the amylin pancreas hormone, led the stock higher last month. Novo Nordisk said Wednesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results